{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:12:02Z","timestamp":1769163122463,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006384","name":"American College of Radiology Imaging Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtho.2024.07.024","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T13:49:36Z","timestamp":1722865776000},"page":"1618-1629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-396X","authenticated-orcid":false,"given":"David","family":"Kozono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled A.","family":"Tolba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiama N.","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin H.","family":"Dragnev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhanelle E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary W.","family":"Redman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.07.024_bib1","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/1078-0432.CCR-13-3473","article-title":"Lung master protocol (lung-MAP)-A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400","volume":"21","author":"Herbst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.07.024_bib2","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S1470-2045(20)30475-7","article-title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","volume":"21","author":"Redman","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.07.024_bib4","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.07.024_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cllc.2022.06.002","article-title":"Treatment considerations for patients with advanced squamous cell carcinoma of the lung","volume":"23","author":"Santos","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.07.024_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.07.024_bib7","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2147\/OTT.S125397","article-title":"EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?","volume":"10","author":"Joshi","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jtho.2024.07.024_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100940","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: final analysis of the randomised phase 3 LUX-Lung 8 trial","volume":"37","author":"Goss","year":"2021","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.jtho.2024.07.024_bib9","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2022.09.018","article-title":"Squamous cell lung cancer: current landscape and future therapeutic options","volume":"40","author":"Lau","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.07.024_bib10","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/JTO.0000000000000314","article-title":"Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of \u201cmaster protocols\u201d in lung cancer","volume":"9","author":"Malik","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/j.seminoncol.2015.07.009","article-title":"The master protocol concept","volume":"42","author":"Redman","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/gim.2017.247","article-title":"Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature","volume":"20","author":"Schwarze","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.jtho.2024.07.024_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.07.024_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtho.2024.07.024_bib15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2024.07.024_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib17","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3390\/cancers15082288","article-title":"Microsatellite instability: a review of molecular epidemiology and implications for immune checkpoint inhibitor therapy","volume":"15","author":"Kavun","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2024.07.024_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cllc.2020.10.015","article-title":"SWOG S1400A (NCT02154490): A Phase II study of durvalumab for patients with previously treated Stage IV or recurrent squamous cell lung cancer (lung-MAP sub-study)","volume":"22","author":"Borghaei","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.07.024_bib19","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jtho.2019.05.029","article-title":"SWOG S1400B (NCT02785913), a Phase II study of GDC-0032 (taselisib) for previously treated PI3K-positive patients with Stage IV squamous cell lung cancer (lung-MAP sub-study)","volume":"14","author":"Langer","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib20","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.jtho.2019.06.027","article-title":"SWOG S1400C (NCT02154490)-A Phase II study of palbociclib for previously treated cell cycle gene alteration-positive patients with Stage IV squamous cell lung cancer (lung-MAP substudy)","volume":"14","author":"Edelman","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib21","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jtho.2019.05.041","article-title":"SWOG S1400D (NCT02965378), a Phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated Stage IV squamous cell lung cancer (lung-MAP substudy)","volume":"14","author":"Aggarwal","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cllc.2021.01.001","article-title":"Phase 2 study of talazoparib in patients with homologous recombination repair-deficient squamous cell lung cancer: lung-MAP substudy S1400G","volume":"22","author":"Owonikoko","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.07.024_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cllc.2020.09.013","article-title":"A\u00a0Phase II study of Telisotuzumab Vedotin in patients with c-MET-positive Stage IV or recurrent squamous cell lung cancer (LUNG-MAP sub-study S1400K, NCT03574753)","volume":"22","author":"Waqar","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.07.024_bib24","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jamaoncol.2021.2209","article-title":"Nivolumab plus ipilimumab vs Nivolumab for previously treated patients with Stage IV squamous cell lung cancer: the lung-MAP S1400I Phase 3 randomized clinical trial","volume":"7","author":"Gettinger","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib25","article-title":"Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1\/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)","volume":"9","author":"Leighl","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.07.024_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1101\/gr.125567.111","article-title":"Mutual exclusivity analysis identifies oncogenic network modules","volume":"22","author":"Ciriello","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.jtho.2024.07.024_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1101\/gr.120477.111","article-title":"De novo discovery of mutated driver pathways in cancer","volume":"22","author":"Vandin","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.jtho.2024.07.024_bib28","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ajhg.2015.12.021","article-title":"MEGSA: A powerful and flexible framework for analyzing mutual exclusivity of tumor mutations","volume":"98","author":"Hua","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtho.2024.07.024_bib30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ccell.2017.06.010","article-title":"Conditional selection of genomic alterations dictates cancer evolution and oncogenic dependencies","volume":"32","author":"Mina","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.07.024_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160519","article-title":"Lollipops in the clinic: information dense mutation plots for precision medicine","volume":"11","author":"Jay","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.07.024_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.07.024_bib33","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/elps.1150181505","article-title":"Swiss-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling","volume":"18","author":"Guex","year":"1997","journal-title":"Electrophoresis"},{"key":"10.1016\/j.jtho.2024.07.024_bib34","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","article-title":"Clustal W and Clustal X version 2.0","volume":"23","author":"Larkin","year":"2007","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jtho.2024.07.024_bib35","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and pathological characteristics of KEAP1- and NFE2L2-mutated non-small cell lung carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.07.024_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41588-019-0569-6","article-title":"Genomic landscape of lung adenocarcinoma in East Asians","volume":"52","author":"Chen","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2024.07.024_bib37","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.07.024_bib38","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41467-019-09374-9","article-title":"Diagnosis of fusion genes using targeted RNA sequencing","volume":"10","author":"Heyer","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.07.024_bib39","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1128\/MCB.24.16.7130-7139.2004","article-title":"Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2","volume":"24","author":"Kobayashi","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jtho.2024.07.024_bib40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1101\/gad.13.1.76","article-title":"Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain","volume":"13","author":"Itoh","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.jtho.2024.07.024_bib41","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1371\/journal.pmed.0030420","article-title":"Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer","volume":"3","author":"Singh","year":"2006","journal-title":"PLOS Med"},{"key":"10.1016\/j.jtho.2024.07.024_bib42","doi-asserted-by":"crossref","first-page":"13568","DOI":"10.1073\/pnas.0806268105","article-title":"Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy","volume":"105","author":"Shibata","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2024.07.024_bib43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1006\/geno.1999.6024","article-title":"Identification of a novel gene (ADPRTL1) encoding a potential Poly(ADP-ribosyl)transferase protein","volume":"62","author":"Still","year":"1999","journal-title":"Genomics"},{"key":"10.1016\/j.jtho.2024.07.024_bib44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1530\/ERC-15-0359","article-title":"Germline PARP4 mutations in patients with primary thyroid and breast cancers","volume":"23","author":"Ikeda","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jtho.2024.07.024_bib45","doi-asserted-by":"crossref","first-page":"8846","DOI":"10.1158\/0008-5472.CAN-05-0770","article-title":"Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis","volume":"65","author":"Raval-Fernandes","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.07.024_bib46","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.21037\/tlcr-20-1197","article-title":"Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma","volume":"10","author":"Pati\u00f1o-Garc\u00eda","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2024.07.024_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-019-05286-w","article-title":"Assessment of PARP4 as a candidate breast cancer susceptibility gene","volume":"177","author":"Prawira","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jtho.2024.07.024_bib48","first-page":"5","article-title":"Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors","volume":"29","author":"L\u2019Esp\u00e9rance","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5483\/BMBRep.2022-0202","article-title":"Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance","volume":"56","author":"Sung","year":"2023","journal-title":"BMB Rep"},{"key":"10.1016\/j.jtho.2024.07.024_bib50","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1083\/jcb.146.5.917","article-title":"The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase","volume":"146","author":"Kickhoefer","year":"1999","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jtho.2024.07.024_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1748-717X-4-29","article-title":"Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression","volume":"4","author":"Lara","year":"2009","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jtho.2024.07.024_bib52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00744212","article-title":"Relationship of LRP-human major vault protein to in\u00a0vitro and clinical resistance to anticancer drugs","volume":"19","author":"Izquierdo","year":"1996","journal-title":"Cytotechnology"},{"key":"10.1016\/j.jtho.2024.07.024_bib53","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1039\/D1MD00195G","article-title":"Rational design of selective inhibitors of PARP4","volume":"12","author":"Kirby","year":"2021","journal-title":"RSC Med Chem"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424007512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424007512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T01:10:29Z","timestamp":1764551429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424007512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1556086424007512"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.07.024","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}